An experimental cancer vaccine by Moderna and Merck demonstrated positive outcomes in its first late-stage trial, advancing closer to potential regulatory approval.
The study involved over 1,100 patients
Aug 20, 2026
09:35 am
What's the storyMerck and Moderna's personalized cancer vaccine has shown promising results in its first late-stage trial.
The mRNA-based shot, when used with Merck's immunotherapy Keytruda, met key goals in a Phase 3 study involving over 1,100 patients with advanced melanoma, a type of skin cancer.
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
The Phase 3 INTerpath-001 trial delivered oncology's first personalised cancer vaccine win, and mRNA a therapeutic breakthrough…
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients.…
Merck and Moderna’s personalized mRNA cancer vaccine helps prevent melanoma recurrence and spread, raising hopes for use against…
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their…
The companies — and others — are testing similar approaches against lung, breast and pancreatic cancers.
